NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/19/2026 15:26
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,117.09 mln
Float57.84 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
119
Exceptional upside
Relative Strength
24
/ 100
Significantly lagging
Debt / Equity
0.01
Debt-free
ROE
-34.00
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Apogee Therapeutics is a US-based clinical-stage biotech company focused on developing new antibody-based medicines for inflammatory and immune-related conditions, including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. Its leading drug candidate, Zumilokibart, is currently in Phase 2 trials for atopic dermatitis and Phase 1 trials for asthma and eosinophilic esophagitis, while several other candidates are progressing through early-stage testing for similar conditions. Founded in 2022 and headquartered in Waltham, Massachusetts, the company is building a pipeline aimed at addressing a range of conditions driven by an overactive immune system.
